Radiopharm Theranostics Files November 2025 6-K Report
Ticker: RDPTF · Form: 6-K · Filed: Nov 25, 2025 · CIK: 1949257
| Field | Detail |
|---|---|
| Company | Radiopharm Theranostics Ltd (RDPTF) |
| Form Type | 6-K |
| Filed Date | Nov 25, 2025 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, foreign-private-issuer, administrative
TL;DR
Radiopharm Theranostics filed its monthly 6-K, confirming 20-F annual report filings.
AI Summary
Radiopharm Theranostics Limited, a foreign private issuer, filed a Form 6-K on November 25, 2025. This filing is for the month of November 2025 and indicates the company will file annual reports under Form 20-F. The company's principal executive office is located at Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia.
Why It Matters
This filing provides routine updates for foreign private issuers, informing investors about the company's reporting status and administrative details.
Risk Assessment
Risk Level: low — This is a routine administrative filing for a foreign private issuer and does not contain significant new financial or operational information.
Key Players & Entities
- Radiopharm Theranostics Limited (company) — Registrant
- 001-41621 (company) — Commission File Number
- Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (company) — Principal executive office address
- Form 20-F (company) — Annual report form
- Form 6-K (company) — Filing type
FAQ
What is the purpose of a Form 6-K filing?
A Form 6-K is a report of foreign private issuers pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934, used to furnish information to the SEC.
Which annual report form does Radiopharm Theranostics Limited indicate it will file?
Radiopharm Theranostics Limited indicates it will file annual reports under cover of Form 20-F.
What is the filing date of this Form 6-K?
This Form 6-K was filed as of November 25, 2025.
Where is Radiopharm Theranostics Limited's principal executive office located?
The principal executive office is located at Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia.
Is Radiopharm Theranostics Limited furnishing information under Rule 12g3-2(b)?
No, the box indicating furnishing information under Rule 12g3-2(b) is not marked ('No').
Filing Stats: 328 words · 1 min read · ~1 pages · Grade level 18.4 · Accepted 2025-11-25 06:48:22
Filing Documents
- ea0267103-6k_radio.htm (6-K) — 13KB
- ea026710301ex99-1_radio.htm (EX-99.1) — 20KB
- ea026710301ex99-2_radio.htm (EX-99.2) — 21KB
- 0001213900-25-114377.txt ( ) — 55KB
From the Filing
OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of November 2025 Commission File Number: 001-41621 RADIOPHARM THERANOSTICS LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934. Yes No If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82- RADIOPHARM THERANOSTICS LIMITED EXPLANATORY NOTE Radiopharm Theranostics Limited (the “Company”) published two announcements (the “Public Notice”) to the Australian Securities Exchange on November 25, 2025 titled: “Final Director’s Interest Notice - LA” “Final Director’s Interest Notice - PH” A copy of the Public Notice is attached as an exhibit to this report on Form 6-K. This report on Form 6-K (including the exhibit hereto) shall not be deemed to be “filed” for purposes of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing. 1 EXHIBITS Exhibit Number Description 99.1 Final Director’s Interest Notice - LA 99.2 Final Director’s Interest Notice - PH 2 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. RADIOPHARM THERANOSTICS LIMITED Date: November 25, 2025 By: /s/ Phillip Hains Phillip Hains Company Secretary 3